Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Humacyte, Inc. - Common Stock (NQ:HUMA)

0.6454 +0.0384 (+6.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
(HUMA) - Analyzing Humacyte's Short Interest ↗
 
Via Benzinga
News headline image
Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK - (NewMediaWire) - October 21, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Kaplan Fox &amp; Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
NEW YORK, NY - (NewMediaWire) - October 19, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
News headline image
How Is The Market Feeling About Humacyte? ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Humacyte? ↗
 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in Humacyte ↗
 
Via Benzinga
News headline image
(HUMA) - Analyzing Humacyte's Short Interest ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
HUMA Stock Earnings: Humacyte Misses EPS for Q2 2024 ↗
HUMA stock results show that Humacyte missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review ↗
FDA extends review timeline for Humacyte's FDA marketing application for its acellular tissue-engineered vessel in vascular trauma. Originally set for August 2024, the new action date remains... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! 
Via InvestorPlace
News headline image
Peering Into Humacyte's Recent Short Interest ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Humacyte? ↗
 
Via Benzinga
News headline image
Peering Into Humacyte's Recent Short Interest ↗
 
Via Benzinga
News headline image
Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803% ↗
Macro environment favors large-caps, but July saw impressive gains for small-caps, with Serve Robotics leading at 803% and Q32 Bio at 101%. 
Via Benzinga
News headline image
Three Small-Cap Stocks to Buy Before a September-Rate-Cut Rally ↗
Discover three small-cap stocks to buy before the Fed acts on interest rates as these small-cap stocks will utilize any cuts to multiply. 
Via InvestorPlace
Topics Economy
News headline image
What's Going On With Huamacyte Shares Tuesday? ↗
Humacyte has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT)... 
Via Benzinga
News headline image
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
MicroStrategy, Coinbase, Robinhood, Tesla And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
From Pluristyx
Via Business Wire
News headline image
Why Humacyte Stock Is Trading 15% Higher Monday ↗
Humacyte received the Food and Drug Administration's Regenerative Medicine Advanced Therapy designation for its Acellular Tissue Engineered Vessel. 
Via Benzinga
News headline image
Tommy Tuberville Sells Several Large Stock Positions, Makes New Buys: Here's What The US Senator Is Betting On Now ↗
Senator Tommy Tuberville disclosed numerous stock trades on Friday June 14. A look at some of the key highlights. 
Via Benzinga
News headline image
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why American Eagle Outfitters Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
HUMA Stock Earnings: Humacyte Misses EPS for Q1 2024 ↗
HUMA stock results show that Humacyte missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.